Particularly, sorafenib, the first molecular targeted drug utilized for unresectable or metastatic HCC treatment, stands out as one of the first-line therapeutic agents in systemic treatments, especially for advanced HCC.[59] Recent studies suggest that the combination of PD-L1 inhibitor atezolizumab and the vascular endothelial growth factor inhibitor bevacizumab demonstrates better overall and progression-free clinical outcomes than those of sorafenib.[10,60,61] PD-L1 inhibitors induce strong immune responses across various cancers. The gene discussed is CD274; the disease is cancer.